Human vascular wall mesenchymal stromal cells contribute to abdominal aortic aneurysm pathogenesis through an impaired immunomodulatory activity and increased levels of matrix metalloproteinase-9

Circulation Journal

Volumn 79, Issue 7, 2015, Pages 1460-1469

  Ciavarella, Carmen ^a   Alviano, Francesco ^a   Gallitto, Enrico ^a   Ricci, Francesca ^b   Buzzi, Marina ^b   Velati, Claudio ^b   Stella, Andrea ^a   Freyrie, Antonio ^a   Pasquinelli, Gianandrea ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Abdominal aortic aneurysm; Human aortic wall; Immunomodulation; Matrix metalloproteinase 9 (MMP9); Mesenchymal stromal cells

Indexed keywords

BIOLOGICAL MARKER; GELATINASE A; GELATINASE B; HLA G ANTIGEN; IL10 PROTEIN, HUMAN; IMMUNOLOGIC FACTOR; INTERLEUKIN 10; MESSENGER RNA; MMP2 PROTEIN, HUMAN; MMP9 PROTEIN, HUMAN;

ABDOMINAL AORTA; AGED; AORTIC ANEURYSM, ABDOMINAL; COCULTURE; DISEASE COURSE; GENETICS; HUMAN; IMMUNOLOGY; MALE; MESENCHYMAL STROMA CELL; METABOLISM; MIDDLE AGED; PARACRINE SIGNALING; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY;

AGED; AORTA, ABDOMINAL; AORTIC ANEURYSM, ABDOMINAL; BIOMARKERS; COCULTURE TECHNIQUES; DISEASE PROGRESSION; HLA-G ANTIGENS; HUMANS; IMMUNOLOGIC FACTORS; INTERLEUKIN-10; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MESENCHYMAL STROMAL CELLS; MIDDLE AGED; PARACRINE COMMUNICATION; RNA, MESSENGER;

EID: 84934300934     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-14-0857     Document Type: Article

References (30)

1. Kurosawa K, Matsumura JS, Yamanouchi D. Current status of medical treatment for abdominal aortic aneurysm. Circ J 2013; 77: 2860-2866.
2. Aggarwal S, Qamar A, Sharma V, Sharma A. Abdominal aortic aneurysm: A comprehensive review. Exp Clin Cardiol 2011; 16: 11-15.
3. Cornuz J, Pinto CS, Tevaearai H, Egger M. Risk factors for asymptomatic abdominal aortic aneurysm. Eur J of Pub Health 2004; 14: 343-349.
4. JCS Joint Working Group. Guidelines for diagnosis and treatment of aortic aneurysm and aortic dissection (JCS 2011): Digest version. Circ J 2013; 77: 789-828.
5. Shimizu K, Mitchell RN, Libby P. Inflammation and cellular immune responses in abdominal aortic aneurysms. Arterioscler Thromb Vasc Biol 2006; 26: 987-994.
6. Miyake T, Morishita R. Pharmacological treatment of abdominal aortic aneurysm. Cardiovasc Res 2009; 83: 436-443.
7. Cafueri G, Parodi F, Pistorio A, Bertolotto M, Ventura F, Gambini C, et al. Endothelial and smooth muscle cells from abdominal aortic aneurysm have increased oxidative stress and telomere attrition. Plose One 2012; 7: e35312, doi:10.1371/journal.pone.0035312.
8. Raffetto JD, Khalil RA. Matrix metalloproteinases and their inhibitors in vascular remodeling and vascular disease. Biochem Pharmacol 2008; 75: 346-359.
9. Benjamin MM, Khalil RA. Matrix metalloproteinases inhibitors as investigative tools in the pathogenesis and management of vascular disease. EXS 2012; 103: 209-279.
10. McMillan WD, Patterson BK, Keen RR, Shively VP, Cipollone M, Pearce WH. In situ localization and quantification of mRNA for 92-kD type IV collagenase and its inhibitor in aneurysmal, occlusive, and normal aorta. Arterioscler Thromb Vasc Biol 1995; 15: 1139-1144.
11. Loftus IM, Naylor AR, Goodall S, Crowther M, Jones L, Bell PR, et al. Increased matrix metalloproteinase-9 activity in unstable carotid plaques: A potential role in acute plaque disruption. Stroke 2000; 31: 40-47.
12. Cheng XW, Song H, Sasaki T, Hu L, Inoue A, Bando YK, et al. Angiotensin type 1 receptor blocker reduces intimal neovascularization and plaque growth in apolipoprotein E-deficient mice. Hypertension 2011; 57: 981-989.
13. Onal IK, Altun B, Onal ED, Kirkpantur A, Gul Oz S, Turgan C. Serum levels of MMP-9 and TIMP-1 in primary hypertension and effect of antihypertensive treatment. Eur J Intern Med 2009; 20: 369-372.
14. Sakata K, Hamaoka K, Ozawa S, Niboshi A, Yahata T, Fujii M, et al. Matrix metalloproteinase-9 in vascular lesions and endothelial regulation in Kawasaki disease. Circ J 2010; 74: 1670-1675.
15. Tamarina NA, McMillan WD, Shively VP, Pearce WH. Expression of matrix metalloproteinases and their inhibitors in aneurysms and normal aorta. Surgery 1997; 122: 264-272.
16. Longo GM, Xiong W, Greiner TC, Zhao Y, Fiotti N, Baxter BT. Matrix metalloproteinases 2 and 9 work in concert to produce aortic aneurysms. J Clin Invest 2002; 110: 625-632.
17. Huusko T, Salonurmi T, Taskinen P, Liinamaa J, Juvonen T, Pääkkö P, et al. Elevated messenger RNA expression and plasma protein levels of osteopontin and matrix metalloproteinase types 2 and 9 in patients with ascending aortic aneurysms. J Thorac Cardiovasc Surg 2013; 145: 1117-1123.
18. Ergün S, Tilki D, Klein D. Vascular wall as a reservoir for different types of stem and progenitor cells. Antioxid Redox Signal 2011; 15: 981-995.
19. Pasquinelli G, Pacilli A, Alviano F, Foroni L, Ricci F, Valente S, et al. Multidistrict human mesenchymal vascular cells: Pluripotency and stemness characteristics. Cytotherapy 2010; 12: 275-287.
20. Valente S, Alviano F, Ciavarella C, Buzzi M, Ricci F, Tazzari PL, et al. Human cadaver multipotent stromal/stem cells isolated from arteries stored in liquid nitrogen for 5 years. Stem Cell Res Ther 2014; 5: 8, doi:10.1186/scrt397.
21. Singer NG, Caplan AI. Mesenchymal stem cells: Mechanisms of inflammation. Annu Rev Pathol 2011; 6: 457-478.
22. Parolini O, Alviano F, Bagnara GP, Bilic G, Bühring HJ, Evangelista M, et al. Concise review: Isolation and characterization of cells from human term placenta: Outcome of the First International Workshop on Placenta Derived Stem Cells. Stem Cells 2008; 26: 300-311.
23. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 2001; 25: 402-408.
24. Boyer LA, Lee TI, Cole MF, Johnstone SE, Levine SS, Zucker JP, et al. Core transcriptional regulatory circuitry in human embryonic stem cells. Cell 2005; 122: 947-956.
25. Nabeshima K, Iwasaki H, Koga K, Hojo H, Suzumiya J, Kikuchi M. Emmprin (basigin/CD147): Matrix metalloproteinase modulator and multifunctional cell recognition molecule that plays a critical role in cancer progression. Pathol Int 2006; 56: 359-367.
26. Yoon YW, Kwon HM, Hwang KC, Choi EY, Hong BK, Kim D, et al. Upstream regulation of matrix metalloproteinase by EMMPRIN; extracellular matrix metalloproteinase inducer in advanced atherosclerotic plaque. Atherosclerosis 2005; 180: 37-44.
27. Seta N, Kuwana M. Derivation of multipotent progenitors from human circulating CD14+ monocytes. Exp Hemat 2010; 38: 557-563.
28. Ries C, Egea V, Karow M, Kolb H, Jochum M, Neth P. MMP-2, MT1-MMP, and TIMP-2 are essential for the invasive capacity of human mesenchymal stem cells: Differential regulation by inflammatory cytokines. Blood 2007; 109: 4055-4063.
29. Chen XF, Wang JA, Hou J, Gui C, Tang LJ, Chen XQ, et al. Extracellular matrix metalloproteinase inducer (EMMPRIN) is present in smooth muscle cells of human aneurysmal aorta and is induced by angiotensin II in vitro. Clin Sci (Lond) 2009; 116: 819-826.
30. Rizzo R, Lanzoni G, Stignani M, Campioni D, Alviano F, Ricci F, et al. A simple method for identifying bone marrow mesenchymal stromal cells with a high immunosuppressive potential. Cytotherapy 2011; 13: 523-527.